147 related articles for article (PubMed ID: 12650703)
1. A mechanism of drug resistance to tamoxifen in breast cancer.
Schafer JM; Bentrem DJ; Takei H; Gajdos C; Badve S; Jordan VC
J Steroid Biochem Mol Biol; 2002 Dec; 83(1-5):75-83. PubMed ID: 12650703
[TBL] [Abstract][Full Text] [Related]
2. Cross-resistance of triphenylethylene-type antiestrogens but not ICI 182,780 in tamoxifen-stimulated breast tumors grown in athymic mice.
Lee ES; Schafer JM; Yao K; England G; O'Regan RM; De Los Reyes A; Jordan VC
Clin Cancer Res; 2000 Dec; 6(12):4893-9. PubMed ID: 11156249
[TBL] [Abstract][Full Text] [Related]
3. Reversal of tamoxifen resistant breast cancer by low dose estrogen therapy.
Osipo C; Gajdos C; Cheng D; Jordan VC
J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):249-56. PubMed ID: 15860267
[TBL] [Abstract][Full Text] [Related]
4. Novel antitumor effect of estradiol in athymic mice injected with a T47D breast cancer cell line overexpressing protein kinase Calpha.
Chisamore MJ; Ahmed Y; Bentrem DJ; Jordan VC; Tonetti DA
Clin Cancer Res; 2001 Oct; 7(10):3156-65. PubMed ID: 11595710
[TBL] [Abstract][Full Text] [Related]
5. Antitumor action of physiological estradiol on tamoxifen-stimulated breast tumors grown in athymic mice.
Yao K; Lee ES; Bentrem DJ; England G; Schafer JI; O'Regan RM; Jordan VC
Clin Cancer Res; 2000 May; 6(5):2028-36. PubMed ID: 10815929
[TBL] [Abstract][Full Text] [Related]
6. Analysis of cross-resistance of the selective estrogen receptor modulators arzoxifene (LY353381) and LY117018 in tamoxifen-stimulated breast cancer xenografts.
Schafer JM; Lee ES; Dardes RC; Bentrem D; O'Regan RM; De Los Reyes A; Jordan VC
Clin Cancer Res; 2001 Aug; 7(8):2505-12. PubMed ID: 11489833
[TBL] [Abstract][Full Text] [Related]
7. Rapid development of tamoxifen-stimulated mutant p53 breast tumors (T47D) in athymic mice.
Schafer JM; Lee ES; O'Regan RM; Yao K; Jordan VC
Clin Cancer Res; 2000 Nov; 6(11):4373-80. PubMed ID: 11106256
[TBL] [Abstract][Full Text] [Related]
8. Paradoxical action of fulvestrant in estradiol-induced regression of tamoxifen-stimulated breast cancer.
Osipo C; Gajdos C; Liu H; Chen B; Jordan VC
J Natl Cancer Inst; 2003 Nov; 95(21):1597-608. PubMed ID: 14600092
[TBL] [Abstract][Full Text] [Related]
9. Investigation of the mechanism of tamoxifen-stimulated breast tumor growth with nonisomerizable analogues of tamoxifen and metabolites.
Wolf DM; Langan-Fahey SM; Parker CJ; McCague R; Jordan VC
J Natl Cancer Inst; 1993 May; 85(10):806-12. PubMed ID: 8487325
[TBL] [Abstract][Full Text] [Related]
10. Dietary flaxseed interaction with tamoxifen induced tumor regression in athymic mice with MCF-7 xenografts by downregulating the expression of estrogen related gene products and signal transduction pathways.
Chen J; Power KA; Mann J; Cheng A; Thompson LU
Nutr Cancer; 2007; 58(2):162-70. PubMed ID: 17640162
[TBL] [Abstract][Full Text] [Related]
11. In Vitro and In Vivo Effects of Jia-Wei-Xiao-Yao-San in Human Breast Cancer MCF-7 Cells Treated With Tamoxifen.
Chen JL; Chang CJ; Wang JY; Wen CS; Tseng LM; Chang WC; Noomhorm N; Liu HJ; Chen WS; Chiu JH; Shyr YM
Integr Cancer Ther; 2014 May; 13(3):226-39. PubMed ID: 24525674
[TBL] [Abstract][Full Text] [Related]
12. Rationale for sequential tamoxifen and anticancer drugs in adjuvant setting for patients with node- and receptor-positive breast cancer.
Kim R; Tanabe K; Emi M; Uchida Y; Osaki A; Toge T
Int J Oncol; 2005 Apr; 26(4):1025-31. PubMed ID: 15753998
[TBL] [Abstract][Full Text] [Related]
13. Regulation of estrogen receptor and epidermal growth factor receptor by tamoxifen under high and low estrogen environments in MCF-7 cells grown in athymic mice.
Koibuchi Y; Iino Y; Uchida T; Andoh T; Horii Y; Nagasawa M; Horiguchi J; Maemura M; Takei H; Yokoe T; Morishita Y
Oncol Rep; 2000; 7(1):135-40. PubMed ID: 10601607
[TBL] [Abstract][Full Text] [Related]
14. Keratinocyte growth factor (KGF) induces tamoxifen (Tam) resistance in human breast cancer MCF-7 cells.
Chang HL; Sugimoto Y; Liu S; Ye W; Wang LS; Huang YW; Lin YC
Anticancer Res; 2006; 26(3A):1773-84. PubMed ID: 16827106
[TBL] [Abstract][Full Text] [Related]
15. GPR30 as an initiator of tamoxifen resistance in hormone-dependent breast cancer.
Mo Z; Liu M; Yang F; Luo H; Li Z; Tu G; Yang G
Breast Cancer Res; 2013 Nov; 15(6):R114. PubMed ID: 24289103
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of PKCalpha is required to impart estradiol inhibition and tamoxifen-resistance in a T47D human breast cancer tumor model.
Lin X; Yu Y; Zhao H; Zhang Y; Manela J; Tonetti DA
Carcinogenesis; 2006 Aug; 27(8):1538-46. PubMed ID: 16513679
[TBL] [Abstract][Full Text] [Related]
17. The regulatory effect of tamoxifen on fibronectin expression in estrogen-dependent MCF-7 breast carcinoma cells.
Horii Y; Takei H; Koibuchi Y; Horiguchi J; Maemura M; Iino Y; Morishita Y
Oncol Rep; 2006 May; 15(5):1191-5. PubMed ID: 16596185
[TBL] [Abstract][Full Text] [Related]
18. miR-449a Suppresses Tamoxifen Resistance in Human Breast Cancer Cells by Targeting ADAM22.
Li J; Lu M; Jin J; Lu X; Xu T; Jin S
Cell Physiol Biochem; 2018; 50(1):136-149. PubMed ID: 30278449
[TBL] [Abstract][Full Text] [Related]
19. Role for HER2/neu and HER3 in fulvestrant-resistant breast cancer.
Osipo C; Meeke K; Cheng D; Weichel A; Bertucci A; Liu H; Jordan VC
Int J Oncol; 2007 Feb; 30(2):509-20. PubMed ID: 17203234
[TBL] [Abstract][Full Text] [Related]
20. Characterization of tamoxifen stimulated MCF-7 tumor variants grown in athymic mice.
Wolf DM; Jordan VC
Breast Cancer Res Treat; 1994; 31(1):117-27. PubMed ID: 7981452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]